[Pubmed] Exploring rituximab for the treatment of refractory myasthenia gravis: a single-centre experience
Posté : 10 déc. 2025 12:00
BMJ Neurol Open. 2025 Nov 30;7(2):e001130. doi: 10.1136/bmjno-2025-001130. eCollection 2025.
ABSTRACT
BACKGROUND: Myasthenia gravis (MG) is a rare autoimmune disorder that affects neuromuscular transmission, leading to muscle weakness. While most patients respond to standard treatments, approximately 15% remain refractory, prompting interest in alternative therapies. This study examined the use of rituximab in patients with refractory MG at a single centre in Latvia, intending to broaden discussions on treatment strategies.
MATERIALS AND METHODS: The prospective cohort study was conducted at Pauls Stradiņš Clinical University Hospital from November 2022 to March 2024. Refractory MG was defined as failure to achieve adequate disease control despite standard immunosuppressive therapy, including patients with persistent symptoms, recurrent crises or intolerance to medications. Myasthenia Gravis Composite Score (MGCS), Myasthenia Gravis Activities of Daily Living and Myasthenia Gravis Quality of Life (scores at baseline and monthly for 6 months) were completed. Glucocorticosteroid doses were also recorded. Data were analysed using descriptive statistics and Wilcoxon signed-rank test, considering p
Source: https://pubmed.ncbi.nlm.nih.gov/4136803 ... 22+67771e2